Study to Use Oral Losartan to Decrease the Risk of Postoperative Scarring Following (ACL) Reconstruction

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Rush University Medical Center
Study ID
NCT07135687
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • ACL Injury
  • ACL Reconstruction
  • Scar Formation

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Losartan — DRUG
    Two types of losartan capsules will be compounded by combining a broken-up 25mg or 50mg losartan tablet and microcrystalline cellulose placebo filler to eliminate rattling of the broken tablet inside of the capsule. The 25mg losartan capsules will be yellow and the 50 mg losartan capsules will be blue.
  • Placebo — OTHER
    The placebo capsules will consist of microcrystal cellulose and will come in yellow and blue to appear identical to the losartan capsules.

Study Details

The purpose of this study to investigate the effect of using losartan (a blood pressure lowering drug with anti-scarring properties) on preventing primary postoperative arthrofibrosis (formation of abnormal scar tissue) in the knees in participants undergoing anterior cruciate ligament (ACL) repair surgery of their knee.

Key Dates

Start date
Aug 31, 2026
Status verified
Dec 2025
Primary completion
Oct 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
144 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Experimental: Losartan
    The experimental arm (Arm 1) will receive 25mg losartan daily for 3 days followed by 50 mg losartan daily for 25 days.
  • Placebo Comparator: Placebo
    The placebo arm (Arm 2) will receive a placebo tablet with the same appearance and frequency to that of the losartan group.

Primary Outcome Measure

Range of Motion [ Time Frame: 12 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Rush University Medical CenterChicagoIllinois60612
Andrew BI, MD
[email protected]
Jorge Chahla, MD, PhD
[email protected]
Jorge Chahla, MD PhD (PRINCIPAL_INVESTIGATOR)
Andrew Bi, MD PhD (PRINCIPAL_INVESTIGATOR)
Adam Yanke, MD, PhD (SUB_INVESTIGATOR)
Brian Cole, MD (SUB_INVESTIGATOR)
Catherine Yuh, MD (SUB_INVESTIGATOR)

Find similar trials in Chicago, IL

By research site
Rush University Medical Center· Chicago, IL

Related Studies